Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer’s Schiff Nutrition Deal Expands Supplement Portfolio

This article was originally published in The Tan Sheet

Executive Summary

Bayer Chairman Marijn Dekkers says Schiff’s products will complement its existing nutritionals business and provide marketing synergies with some OTCs. Schiff’s Move Free for joint health, MegaRed for heart health, Airborne for immunity and Digestive Advantage probiotics accounted for 70% of its fiscal 2012 sales.

You may also be interested in...



Schiff Nutrition Enlists Airborne For Sortie Into Immune Support

The $150 million price represents more than twice Airborne’s approximately $70 million in annual net revenues for supplements marketed to strengthen immune support. The acquisition from GF Capital follows Pfizer’s recent foray into the immune support space by buying the maker of Emergen-C products.

In Brief

Novartis makes OTC exec change following recall and plant shutdown; Prestige Brands adopts plan to deter Genomma takeover bid; Pfizer scoops up Emergen-C maker Alacer; CSPI threatens Amway with Nutrilite suit; more news In Brief.

Pfizer Builds Nutrition Site To Grow Vitamin Business

The website nutritionpossible.com is Pfizer’s latest effort to improve its consumer segment, including the Centrum vitamins line. The site also offers a health assessment tool for recommending supplements and lifestyle changes to consumers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel